Related Experiment Video
Updated: May 4, 2026
09:38
Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
Published on: January 31, 2025
1.2K
Isolated limb perfusion with melphalan for melanoma
1Melanoma Institute Australia, North Sydney, NSW, Australia.
Journal of Surgical Oncology
|January 15, 2014
Summary
Isolated limb perfusion with melphalan effectively treats extremity melanoma metastases, achieving high response rates. While complex, this surgical technique minimizes side effects when performed meticulously.
Area of Science:
- Oncology
- Surgical Oncology
- Melanoma Research
Background:
- Isolated limb perfusion (ILP) is a critical treatment for unresectable limb melanoma.
- Melphalan is a chemotherapeutic agent used in ILP.
Purpose of the Study:
- To review the technique, outcomes, and management of ILP for extremity melanoma.
- To highlight the efficacy and safety considerations of this specialized treatment.
Main Methods:
- Detailed review of the surgical procedure for isolated limb perfusion.
- Analysis of patient response rates and potential morbidities.
Main Results:
- Overall response rate of 80% for ILP with melphalan.
- Complete response rate of 54% in patients with extremity melanoma metastases.
- Significant morbidity can be minimized through careful surgical execution.
Conclusions:
- Isolated limb perfusion with melphalan is a highly effective treatment for inoperable melanoma metastases of the extremities.
- Meticulous attention to surgical detail is crucial for minimizing serious side effects and optimizing patient outcomes.
